Evidence map›Paper›PMID 40226136›Full record

ArticleIJTLD open2025

Accuracy of Truenat™ MTB Plus for the diagnosis of pulmonary TB.

M C M Melo, A K Silveira, A P R Dalvi, J Silva, V S Printes, L Anselmo, T I da Silva, M M Oliveira, C Conceição, A Lopes and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

M C M MeloInstitute of Thoracic Diseases, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
A K SilveiraInstitute of Thoracic Diseases, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
A P R DalviInstitute of Thoracic Diseases, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
J SilvaMycobacteriology Laboratory, Tropical Medicine Foundation Doctor Heitor Vieira Dourado, Manaus, DF, Brazil.
V S PrintesMycobacteriology Laboratory, Tropical Medicine Foundation Doctor Heitor Vieira Dourado, Manaus, DF, Brazil.
L AnselmoRibeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, SP, Brazil.
T I da SilvaMolecular Mycobacteriology Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
M M OliveiraMolecular Mycobacteriology Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
C ConceiçãoInstitute of Thoracic Diseases, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
A LopesInstitute of Thoracic Diseases, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
V BollelaRibeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, SP, Brazil.
M Cordeiro-SantosMycobacteriology Laboratory, Tropical Medicine Foundation Doctor Heitor Vieira Dourado, Manaus, DF, Brazil.
M BheringInstitute of Thoracic Diseases, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
A S R MoreiraInstitute of Thoracic Diseases, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
A C C CarvalhoLaboratory of Innovation, Therapies, Teaching and Bioproducts, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
A L KritskiInstitute of Thoracic Diseases, Medical School, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTruenat™ is a WHO-recommended rapid molecular test for diagnosing TB and detecting rifampicin resistance, whose performance has been evaluated in a few high TB burden countries.

methodsA prospective multicentre study was conducted in Brazil to estimate the sensitivity and specificity of Truenat MTB Plus compared to Xpert

resultsAmong 283 participants, 112 (39.6%) had culture-positive pulmonary TB. The sensitivity and specificity of Truenat MTB Plus were respectively 72.7% (95% CI 63.41-80.78) and 99.4% (95% CI 96.71-99.98), compared to 78.4% (95% CI 69.56-85.63) and 99.4% (95% CI 96.67-99.98) for Xpert MTB/RIF Ultra. In 89 people living with HIV (PLHIV), Truenat MTB Plus showed a sensitivity of 45.0% (95% CI 23.06-68.47) and specificity of 100.0% (95% CI 95.64-100.00). Among 71 patients previously treated for TB, Truenat MTB Plus showed sensitivity and specificity of respectively 79.3% (95% CI 60.28-92.01) and 97.5% (95% CI 86.84-99.94). Xpert MTB/RIF Ultra detected rifampicin resistance in 11/88 samples (12.5%) vs 9/72 (12.5%) with Truenat MTB Plus.

conclusionThe Truenat MTB Plus performance was comparable to Xpert MTB/RIF Ultra. Both tests demonstrated lower sensitivity in PLHIV.

Indexed as

diagnosisdrug-resistant tuberculosismolecular diagnostic techniquesMycobacterium tuberculosissensitivity and specificity

Identifiers

PMID40226136
PMCPMC11984528

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.